Lys627
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.4
Powered by Cell Signaling Technology
Home > Sumoylation Site Page: > Lys627  -  p73 (human)

Site Information
KARKQPIkEEFTEAE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 2293700

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 2 , 3 ) , immunoprecipitation ( 2 ) , mass spectrometry ( 1 ) , modification-specific antibody ( 2 ) , mutation of modification site ( 2 , 3 ) , western blotting ( 2 )
Disease tissue studied:
bone cancer ( 2 ) , lung cancer ( 2 ) , non-small cell lung cancer ( 2 ) , soft tissue cancer ( 3 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Treatments:
siRNA ( 2 )

Downstream Regulation
Effects of modification on p73:
intracellular localization ( 2 , 3 ) , protein degradation ( 3 )
Effects of modification on biological processes:
cell cycle regulation ( 2 ) , transcription, inhibited ( 2 )

References 

1

Tammsalu T, et al. (2014) Proteome-wide identification of SUMO2 modification sites. Sci Signal 7, rs2
24782567   Curated Info

2

Munarriz E, et al. (2004) PIAS-1 is a checkpoint regulator which affects exit from G1 and G2 by sumoylation of p73. Mol Cell Biol 24, 10593-610
15572666   Curated Info

3

Minty A, Dumont X, Kaghad M, Caput D (2000) Covalent modification of p73alpha by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif. J Biol Chem 275, 36316-23
10961991   Curated Info